• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by CEO, President Mack Gene

    3/21/25 8:00:04 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GANX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Mack Gene

    (Last) (First) (Middle)
    C/O GAIN THERAPEUTICS, INC.
    4800 MONTGOMERY LANE, SUITE 220

    (Street)
    BETHESDA MD 20814

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Gain Therapeutics, Inc. [ GANX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    CEO, President
    3. Date of Earliest Transaction (Month/Day/Year)
    03/20/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (right to buy) $2.29 03/20/2025 A 200,000 (1) 03/20/2035 Common Stock 200,000 $0.00 200,000 D
    Explanation of Responses:
    1. The shares underlying the option shall vest as to 25% on March 20, 2026, and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.
    /s/ Gene Mack 03/21/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GANX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GANX

    DatePrice TargetRatingAnalyst
    3/7/2025$12.00Sector Outperform
    Scotiabank
    12/6/2024$7.00Buy
    ROTH MKM
    8/14/2024$8.00Outperform
    Oppenheimer
    11/3/2021$21.00Buy
    B. Riley Securities
    More analyst ratings

    $GANX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Gain Therapeutics Inc.

      DEFA14A - Gain Therapeutics, Inc. (0001819411) (Filer)

      4/29/25 4:07:47 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Gain Therapeutics Inc.

      DEF 14A - Gain Therapeutics, Inc. (0001819411) (Filer)

      4/29/25 4:05:41 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Gain Therapeutics Inc.

      PRE 14A - Gain Therapeutics, Inc. (0001819411) (Filer)

      4/17/25 4:05:19 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GANX
    Leadership Updates

    Live Leadership Updates

    See more

    $GANX
    Financials

    Live finance-specific insights

    See more

    $GANX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $GANX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $GANX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $GANX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

      Gene Mack Has Served As CFO Since April 2024 And Interim CEO Since June 2024 Gianluca Fuggetta Will Assume The Role Of Senior Vice President, Finance BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, who has served as the Company's Chief Financial Officer since April 2024 and interim Chief Executive Officer since June 2024, has been appointed President and Chief Executive Officer, effective January 6, 2025. Mr. Mack has also been appointed as a me

      1/7/25 7:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

      Mr. Mack is the Company's Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that Matthias Alder has departed the Company in order to pursue other opportunities. Upon Mr. Alder's departure, the Company appointed Gene Mack, the Company's current Chief Financial Officer, as interim Chief Executive Officer, effective June 25, 2024. Mr. Mack will retain his role as Chief Finan

      6/27/24 4:08:08 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

      BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024. "We are thrilled to welcome Gene as our new CFO," commented Gain CEO Matthias Alder. "His experience as an operational CFO with a track record of successful financing, M&A and other strategic transactions combined with his scientific background and career as an equity research analyst ideally complement our executive man

      4/8/24 9:25:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

      BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update. "2024 was a year of significant progress for Gain, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without GBA1 mutation," said Gene Mack, President and CEO

      3/27/25 7:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

      BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended September 30, 2024, and provides a corporate update. "The third quarter of 2024 marked substantial progress for Gain and the development of GT-02287, our lead candidate for the treatment of Parkinson's disease in patients with or without the GBA1 mutation. Data from our Phase 1 study for GT-02287 presented recently at both the International Congress of Parkinson's Disease and Movement

      11/14/24 4:05:00 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

      Company To Discuss Positive Results Presented at the International MDS Congress and the Design of Phase 1b Trial in Parkinson's Disease Patients Event Will Be Held on Monday, September 30, 2024, at 8:30 am ET BETHESDA, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it is holding a webinar to discuss data from the Phase 1 study of GT-02287, a novel GCase-targeting small molecule therapy for Parkinson's disease, recently presented in a late-breaker at the International Congress

      9/26/24 7:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and Interim CEO Mack Gene bought $14,544 worth of shares (14,400 units at $1.01) (SEC Form 4)

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      8/12/24 5:23:31 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive Chairman Islam Khalid bought $49,940 worth of shares (50,000 units at $1.00) (SEC Form 4)

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      8/12/24 5:23:30 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Richman Eric I bought $20,670 worth of shares (17,000 units at $1.22), increasing direct ownership by 6% to 289,629 units (SEC Form 4)

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      7/1/24 5:00:27 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by See Remark Fuggetta Gianluca

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      3/21/25 8:00:09 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CEO, President Mack Gene

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      3/21/25 8:00:04 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CEO, President Mack Gene

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      1/7/25 9:00:08 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Gain Therapeutics Inc.

      SC 13G/A - Gain Therapeutics, Inc. (0001819411) (Subject)

      3/29/21 11:59:04 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Gain Therapeutics with a new price target

      Scotiabank initiated coverage of Gain Therapeutics with a rating of Sector Outperform and set a new price target of $12.00

      3/7/25 8:20:06 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM initiated coverage on Gain Therapeutics with a new price target

      ROTH MKM initiated coverage of Gain Therapeutics with a rating of Buy and set a new price target of $7.00

      12/6/24 7:48:38 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Gain Therapeutics with a new price target

      Oppenheimer resumed coverage of Gain Therapeutics with a rating of Outperform and set a new price target of $8.00

      8/14/24 7:36:01 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GANX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Gain Therapeutics to Participate at The Citizens Life Sciences Conference

      BETHESDA, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present and participate in one-on-one meetings at The Citizens Life Sciences Conference, being held May 7th-8th in New York City, NY. Details of the presentation are as follows: Date: Thursday, May 8, 2025 Time: 12:00 p.m. EST Please contact your representative at Citizens if you would like to set up a one-on-one meeting with management. An archived replay of the presentat

      5/1/25 7:30:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

      BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral poster presentation at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson's Disease and Related Disorders, being held May 7th-10th in New York City, NY. Details of the oral and poster presentation are as follows: Presentation Title: GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson's Disease, Protects Dopaminergic Neu

      4/30/25 7:45:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update

      GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson's disease models Enrollment update provided for Phase 1b study Phase 1b study ongoing to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of GT-02287 in people with Parkinson's disease; biomarker analysis to be conducted in Q2 2025 BETHESDA, Md., April 10, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that an oral presentation as well as a poster were pres

      4/10/25 7:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care